Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Let’s talk integration

October 29th 2019, 08:00 PST; 11:00 EST; 15:00 GMT; 16:00 CET

Sponsored by:

The complexities of integrating processes and scaling-up the manufacturing of cell and gene therapies is a topic that is prevalent in our maturing industry. Vendors and producers are focusing heavilyon developing purpose-built solutions, integrating as many steps as possible, sometimes leveraging entirely new technologies rather than legacy approaches from the blood processing and biologics sector. This can present new challenges as the implementation often impacts process development, automation and regulatory teams within an organization.

This webinar will provide a short example of the ekko™ system processing cell aggregates while integrated with a bioreactor. A cross-functional panel will then discuss integration challenges and learnings related to an integration strategy.

REGISTER



Nina Bauer Lonza Cell Therapy

Nina Bauer, VP Business Development, FloDesign Sonics Inc

Nina Bauer, a key figure in the cell and gene therapy community joined FloDesign Sonics in September as VP of Business Development. She leads the commercial aspects of establishing, launching, and further adoption of this disruptive technology. Previously Nina led Lonza’s Autologous Cell Therapy business, with manufacturing sites in the US and Europe. As part of this role, she was also in charge of establishing novel manufacturing technologies, most notably the Octane Cocoon™ platform. Prior to joining Lonza, Nina held business development roles at the Cell Therapy Catapult (London), and the University of Edinburgh, and worked as Life Science Consultant for regenerative medicine businesses.



Mark Dudley, PhD, SVP, Product Development, Adaptimmune

Dr. Mark Dudley is a Senior Vice President at Adaptimmune Therapeutics, a leader in genetically modified T cell therapies for solid cancers, where he is responsible for manufacturing and development. Dr. Dudley has been a pioneer in the field of immunotherapy manufacturing, and has developed and implemented innovative early process design with accompanying analytics for multiple therapies. Previously, as Director of New Cell Products in the Cell and Gene Therapies division of Novartis Pharmaceutical Corp, Dr Dudley was responsible for establishing scalable, GMP-compliant production strategies and facilitating globalization of CAR-T products and platforms. As Director of the Cell Manufacturing Facility at the Surgery Branch of the National Cancer Institute, NIH, in Bethesda, MD, Dr Dudley investigated tumor rejection antigens, T cell specificity and function, and methods for the generation and administration to patients of T cell therapies. His work has resulted in more than 100 peer-reviewed publications, and he is co-author on numerous seminal papers including early tumor-infiltrating lymphocytes studies demonstrating that adoptive T-cell transfer has tumor eradicating potential. Dr. Dudley earned a Ph.D. in Biological Sciences at Stanford University, and had post-doctoral fellowships at The University of Pennsylvania in Philadelphia, PA and at the Jackson Laboratory in Bar Harbor, ME.


Richard Hammond, Technology Director and Head of Synthetic Biology, Cambridge Consultants


Twitter IconVisit Our Blog